Studying rosuvastatin to slow liver scarring in cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have cirrhosis caused by nonalcoholic fatty liver disease (NASH), alcohol-related liver disease, or hepatitis B or C (treated and controlled)
- You can show cirrhosis using recent medical testing (like a recent biopsy, liver scans, or stiffness measurements)
- Your cirrhosis must be “compensated,” meaning no ascites (fluid), no confusion from liver disease, and no recent bleeding from enlarged veins
- Your liver stiffness test (elastography) must be high at screening and at the next visit, with specific timing between tests
- You have not taken a statin in the past 24 weeks and do not need it for specific heart/stroke prevention reasons
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.
This trial tests whether adding a statin (simvastatin) to the usual heart medication carvedilol helps people with both cirrhosis and a related heart problem live longer and avoid serious liver complications.
This trial tests if adding a statin to beta blocker treatment helps people with advanced liver disease (cirrhosis) who have had complications like fluid buildup, confusion, or bleeding. It is for patients who are already taking a non-selective beta blocker and will be followed for 12 months.
This study looks at how your body uses protein in your muscles when you have cirrhosis (a scarred liver). It uses a special “tracer” method (a substance that can be tracked) and may help researchers better understand muscle loss in people with milder cirrhosis.
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.